Bora CDMO Bora CDMO

X

Find the latest Drugs in Development and Pipeline Prospector News of Klinge Pharma.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Klinge Pharma
Germany Flag
Country
Country
Germany
Address
Address
Bergfeldstraße 9, 83607 Holzkirchen
Telephone
Telephone
+49 (0) 800/5546430
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

FYB203, a biosimilar candidate to Eylea (aflibercept), which Klinge Biopharma has in-licensed from the German biosimilar developer Formycon AG, is being evaluated in a Phase 3 clinical trial in patients with Neovascular (wet) Age-Related Macular Degeneration (nAMD).


Lead Product(s): Aflibercept

Therapeutic Area: Ophthalmology Product Name: FYB203

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Coherus Biosciences

Deal Size: Undisclosed Upfront Cash: $32.5 million

Deal Type: Acquisition January 09, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY